Studying patient-reported vision function adds dimension and meaning beyond visual acuity to clinical studies and patient care. One metric of function is the ability to drive–an ability frequently lost with center-vision involved DME caused by diabetes mellitus. A study published in JAMA Opthalmology this month shows the relationship between ranibizumab treatment for DME and the ability to drive. After 12 months of ranibizumab treatment, patients not driving at initiation of treatment are more likely to report driving and have driving-eligible visual acuity of 20/40 or better in the better-seeing eye than those treated with sham or laser.
Sorry, comments are closed for this post.